Vera Therapeutics Inc (VERA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vera Therapeutics Inc (VERA) has a cash flow conversion efficiency ratio of -0.116x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-69.99 Million) by net assets ($604.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Vera Therapeutics Inc to measure how much of total assets are equity-financed.
Vera Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Vera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore VERA long-term investment intensity to see how much of total assets are deployed in long-term investments.
Vera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vera Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allied Gold Corporation
TO:AAUC
|
0.432x |
|
Sime Darby Property Bhd
KLSE:5288
|
-0.006x |
|
Netcompany Group A/S
CO:NETC
|
0.024x |
|
Tianma Microelectronics Co Ltd
SHE:000050
|
0.018x |
|
Nanjing Sunlord Electronics Corporation LTD
SHE:300975
|
-0.001x |
|
Select Energy Services Inc
NYSE:WTTR
|
0.009x |
|
Perpetua Resources Corp
NASDAQ:PPTA
|
-0.069x |
|
ZIP Co Ltd
AU:ZIP
|
-0.205x |
Annual Cash Flow Conversion Efficiency for Vera Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Vera Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Vera Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $604.52 Million | $-241.10 Million | -0.399x | -70.92% |
| 2024-12-31 | $577.15 Million | $-134.68 Million | -0.233x | +74.26% |
| 2023-12-31 | $101.69 Million | $-92.18 Million | -0.907x | -3.14% |
| 2022-12-31 | $76.91 Million | $-67.60 Million | -0.879x | -158.00% |
| 2021-12-31 | $69.59 Million | $-23.71 Million | -0.341x | -187.44% |
| 2020-12-31 | $-89.35 Million | $-34.81 Million | 0.390x | +38.39% |
| 2019-12-31 | $-36.55 Million | $-10.29 Million | 0.282x | -- |
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous in… Read more